Latest period
−$1.58B
YoY change
-49.1%
5Y CAGR
—
Peak year (2021)
$13.34B
Latest annual
−$2.06B
Free Cash Flow history chart for Moderna (MRNA) from 2016 to 2025
Latest: −$2.06B
Free Cash Flow growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -49.1%
Free Cash Flow history table for Moderna (MRNA) from 2016 to 2025
| 2025 | −$2.06B | -49.1% | +$1.99B | ||
| 2024 | −$4.05B | +6.0% | −$230.00M | ||
| 2023 | −$3.83B | -183.5% | −$8.41B | ||
| 2022 | $4.58B | -65.6% | −$8.76B | ||
| 2021 | $13.34B | +580.6% | +$11.38B | ||
| 2020 | $1.96B | -499.5% | +$2.45B | ||
| 2019 | −$490.52M | +12.3% | −$53.89M | ||
| 2018 | −$436.63M | +12.0% | −$46.75M | ||
| 2017 | −$389.88M | -1260.7% | −$423.48M | ||
| 2016 | $33.59M | — | — |
- 2025−$2.06B-49.1%
- 2024−$4.05B+6.0%
- 2023−$3.83B-183.5%
- 2022$4.58B-65.6%
- 2021$13.34B+580.6%
- 2020$1.96B-499.5%
- 2019−$490.52M+12.3%
- 2018−$436.63M+12.0%
- 2017−$389.88M-1260.7%
- 2016$33.59M—
Free Cash Flow values are taken from Moderna's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Moderna (MRNA)
Free Cash Flow for Moderna (MRNA): headline value −$1.58B · YoY -49.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Moderna (MRNA) reported free cash flow of −$2.06B – plunged 49.1% year-over-year.
Moderna free cash flow plunged from $13.34B in 2021 to −$2.06B in 2025, a 115.5% drawdown.
2021 marks the peak free cash flow at $13.34B, with the historical low of −$4.05B recorded in 2024.
Moderna Free Cash Flow by Year
Moderna Free Cash Flow 2025: −$2.06B
Moderna posted free cash flow of −$2.06B in 2025, plunged 49.1% below 2024.
Moderna Free Cash Flow 2024: −$4.05B
In 2024, Moderna reported free cash flow of −$4.05B, grew 6.0% from 2023. This figure represents the lowest annual value in the available history.
Moderna Free Cash Flow 2023: −$3.83B
Moderna free cash flow in 2023 was −$3.83B, plunged 183.5% below 2022.
Moderna Free Cash Flow 2022: $4.58B
2022's free cash flow for Moderna came in at $4.58B, plunged 65.6% below 2021.
Moderna Free Cash Flow 2021: $13.34B
Moderna free cash flow in 2021 was $13.34B.
See more financial history for Moderna (MRNA).
Sector peers by Free Cash Flow
Healthcare peers of Moderna (MRNA), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $8.97B | |
| $8.67B | |
| $8.10B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $8.97B
- $8.67B
- $8.10B
- $4.52B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation